Mar 22

A novel method of treating rheumatoid arthritis By Dr Ananya Mandal.

Although in its first stages, the scientists are hopeful that they shall be able to transfer the findings to human beings. This extensive research is quite exciting, as although it is certainly in its early stages, if it could be transferred to humans it could shut down the inflammation that causes rheumatoid arthritis. Work is now underway on improving the properties of PS372424 so medical trials can be executed.. A novel method of treating rheumatoid arthritis By Dr Ananya Mandal, MD Researchers have found a new and potentially exciting way to treat rheumatoid arthritis.Related StoriesTargeting exhausted immune cells may transformation prognosis for leukemia relapse sufferers after transplantPotential new drug target for severe myeloid leukemiaBlocking the creation of CHD4 protein can help increase efficiency of AML treatments At this time, the U.S. Prescribing info for Iclusig is normally unchanged. Iclusig is still obtainable in the U.S. To individuals with resistant or intolerant chronic myeloid leukemia and Philadelphia-chromosome positive severe lymphoblastic leukemia in the industry setting at the authorized, once-daily dosage of 45 mg. ARIAD has been in discussion with the FDA and additional health authorities about adjustments in Iclusig item labeling to reflect the updated information.